




RealRate

PHARMACEUTICAL 2022

Lixte Biotechnology Holdings INC
Rank 278 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 259%, being 16% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	5,093
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	303
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,060
Other Liabilities	0
Other Net Income	-0.54
Other Revenues	0
Property and Equipment	0
Research and Development	1,737
Selling, General and Administrative Expense	2,931

Output Variable	Value in 1000 USD
Assets	5,093
Liabilities	303
Expenses	6,728
Revenues	0
Stockholders Equity	4,790
Net Income	-6,728
Comprehensive Net Income	-6,728
BaseVar	6,062
ECR before LimitedLiability	138%
Economic Capital Ratio	259%